Startup gobbles up $60M from high-profile investors to target food allergies

The company emerges within weeks of Aimmune Therapeutics Inc. winning the first FDA approval of a peanut allergy treatment.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.